An MIF promoter polymorphism is associated with susceptibility to pulmonary arterial hypertension in diffuse cutaneous systemic sclerosis
Metadata
Show full item recordAuthor
López Isac, ElenaEditorial
Journal of Rheumatology Publishing Company
Date
2017Referencia bibliográfica
Bossini-Castillo L, Campillo-Davó D, López-Isac E, Carmona FD, Simeon CP, Carreira P, Callejas-Rubio JL, Castellví I, Fernández-Nebro A, Rodríguez-Rodríguez L, Rubio-Rivas M, García-Hernández FJ, Madroñero AB, Beretta L, Santaniello A, Lunardi C, Airó P, Hoffmann-Vold AM, Kreuter A, Riemekasten G, Witte T, Hunzelmann N, Vonk MC, Voskuyl AE, de Vries-Bouwstra J, Shiels P, Herrick A, Worthington J, Radstake TRDJ, Martin J; Spanish Scleroderma Group. An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis. J Rheumatol. 2017 Oct;44(10):1453-1457. doi: 10.3899/jrheum.161369. Epub 2017 Jul 1. PMID: 28668810.
Sponsorship
This work was supported by the following grants: JM was funded by SAF2015-66761-P from the Spanish Ministry of Economy and Competitiveness. This study was also funded by PI-0590-2010, from Consejería de Salud y Bienestar Social, Junta de Andalucía, Spain. ELI was supported by Ministerio de Educación, Cultura y Deporte through the program FPU.Abstract
Objective. Systemic sclerosis (SSc) is a fibrotic immune-mediated disease of unknown etiology. Among its clinical manifestations, pulmonary involvement is the leading cause of mortality in patients with SSc. However, the genetic factors involved in lung complication are not well defined. We aimed to review the association of the MIF gene, which encodes a cytokine implicated in idiopathic pulmonary hypertension among other diseases, with the susceptibility and clinical expression of SSc, in addition to testing the association of this polymorphism with SSc-related pulmonary involvement.
Methods. A total of 4392 patients with SSc and 16,591 unaffected controls from 6 cohorts of European origin were genotyped for the MIF promoter variant rs755622. An inverse variance method was used to metaanalyze the data.
Results. A statistically significant increase of the MIF rs755622*C allele frequency compared with controls was observed in the subgroups of patients with diffuse cutaneous SSc (dcSSc) and with pulmonary arterial hypertension (PAH) independently (dcSSc: p = 3.20E–2, OR 1.13; PAH: p = 2.19E–02, OR 1.32). However, our data revealed a stronger effect size with the subset of patients with SSc showing both clinical manifestations (dcSSc with PAH: p = 6.91E–3, OR 2.05).
Conclusion. We reviewed the association of the MIF rs755622*C allele with SSc and described a phenotype-specific association of this variant with the susceptibility to develop PAH in patients with dcSSc.